The clinical trial included 432 patients taking INLYTA with pembrolizumab versus 429 patients taking a medicine called sunitinib. The median age of patients in the trial was 62 years old, with 38% of patients being over the age of 65.
In the trial, researchers studied:
47%
INLYTA with pembrolizumab decreased the overall risk of death by 47% compared to sunitinib (Overall survival).
31%
INLYTA with pembrolizumab also decreased the overall risk of disease progression by 31% compared to sunitinib (Progression-free survival or PFS).
INLYTA with pembrolizumab shrank tumor size in more patients than sunitinib (Objective response rate)
59%
of patients had their tumors shrink (256 of 432 patients)
36%
of patients had their tumors shrink (153 of 429 patients)
This includes patients whose tumors shrank 30% or more and whose response to treatment lasted at least 4 weeks.
INLYTA in combination with pembrolizumab is not a cure. The data represent an average of patients in the clinical trial, and not all patients will experience the same results.
The following side effects were the most common among patients in the clinical trial:
Side effects
INLYTA® (axitinib) + pembrolizumab
sunitinib
Diarrhea
56%
45%
Feeling tired or weak
52%
51%
High blood pressure
48%
48%
Liver problems
39%
25%
Low levels of thyroid hormone
35%
32%
Decreased appetite
30%
29%
Redness, itching or peeling of your skin on your hands and feet
28%
40%
Nausea
28%
32%
Mouth sores or swelling of the lining of the mouth, nose, eyes, throat, intestines, or vagina
27%
41%
Hoarseness
25%
3.3%
Rash
25%
21%
Constipation
21%
15%
Cough
21%
14%
INLYTA (axitinib) + pembrolizumab
sunitinib
56%
45%
INLYTA (axitinib) + pembrolizumab
sunitinib
52%
51%
INLYTA (axitinib) + pembrolizumab
sunitinib
48%
48%
INLYTA (axitinib) + pembrolizumab
sunitinib
39%
25%
INLYTA (axitinib) + pembrolizumab
sunitinib
35%
32%
INLYTA (axitinib) + pembrolizumab
sunitinib
30%
29%
INLYTA (axitinib) + pembrolizumab
sunitinib
28%
40%
INLYTA (axitinib) + pembrolizumab
sunitinib
28%
32%
INLYTA (axitinib) + pembrolizumab
sunitinib
27%
41%
INLYTA (axitinib) + pembrolizumab
sunitinib
25%
3.3%
INLYTA (axitinib) + pembrolizumab
sunitinib
25%
21%
INLYTA (axitinib) + pembrolizumab
sunitinib
21%
15%
INLYTA (axitinib) + pembrolizumab
sunitinib
21%
14%
In the clinical trial, some patients had their dose reduced, temporarily paused, or permanently stopped taking their medication to help manage side effects.
76%
of patients temporarily paused treatment or had their dose reduced due to side effects
31%
of patients permanently stopped treatment due to a side effect from either INLYTA or pembrolizumab
If you have any side effects, it's important to tell your healthcare team so they can determine the appropriate ways to help manage your side effects.
Patients in the clinical trial discontinued INLYTA and/or pembrolizumab due to side effects. The percentages above represent treatment breaks, dose reductions, and discontinuation for INLYTA only.
Read Important Safety Information for INLYTA when taken with pembrolizumab. |
|
Before taking INLYTA, tell your healthcare provider about all of your medical conditions, including if you:
For females, tell your healthcare provider if you:
For males with female partners who are able to become pregnant:
INLYTA may cause fertility problems in males and females, which may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. INLYTA and certain other medicines can affect each other causing serious side effects.
Talk with your healthcare provider before you start taking any new medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
Do not drink grapefruit juice or eat grapefruit. Grapefruit may increase the amount of INLYTA in your blood.
INLYTA may cause serious side effects, including:
The most common side effects of INLYTA with pembrolizumab include:
Important information: If your healthcare provider prescribes INLYTA for you to be taken with pembrolizumab, also read the Medication Guide for pembrolizumab.
The most common side effects of INLYTA when used alone include:
These are not all of the possible side effects of INLYTA. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see full Prescribing Information and Patient Information, which includes a complete discussion of the risks of INLYTA.
INLYTA is a prescription medicine used to treat kidney cancer that has spread or cannot be removed by surgery (advanced renal cell carcinoma or RCC):
It is not known if INLYTA is safe and effective in children.
INLYTA is a prescription medicine used to treat kidney cancer that has spread or cannot be removed by surgery (advanced renal cell carcinoma or RCC):
It is not known if INLYTA is safe and effective in children.
A mass of cancer cells.
A disease of the arteries (commonly called high blood pressure).
Located throughout the body, lymph nodes filter lymph fluid. They store special cells that can trap cancer cells or bacteria that are traveling through the body in the lymph.
One of a pair of organs that removes waste products from the blood. In the process, they make urine to help carry waste products out of the body. One is on the left side of the abdomen. The other is on the right side.
INLYTA (axitinib) is a prescription medicine used to treat kidney cancer that has spread or cannot be removed by surgery (advanced renal cell carcinoma or RCC):
It is not known if INLYTA is safe and effective in children.
Cancer that has spread from one part of the body to another through the lymphatic system or bloodstream.